Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

RESICT-PC

Financiado

Cerrado

Studying Resistance to Cancer Therapeutics in Prostate Cancer

Several new therapies have been recently approved for the treatment of castration-resistant prostate cancer (CRPC) but drug resistance invariably develops and eventually causes death. Currently, the knowledge on the molecular mech... ver más

30/04/2016

ICR

231K€

Presupuesto del proyecto: 231K€

Líder del proyecto

INSTITUTE OF CANCER RESEARCH THE ROYAL CANCER... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2016-04-30 No tenemos la información de la convocatoria

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

ICR

0.00€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

TransPot Translational Research Network in Prostate Cancer 3M€ Cerrado

RTI2018-097016-A-I00 BASES MOLECULARES DEL PAPEL DE LA POLIMERASA THETA EN EL CAN... 145K€ Cerrado

STOPCa The cryptic path of tumor microenvironment interactions in p... 175K€ Cerrado

PDX-PC Elucidation of tumour cell plasticity mechanisms associated... 166K€ Cerrado

PCaProTreat Multi omics molecular treatment targets for Prostate Cancer 171K€ Cerrado

PID2020-117650RA-I00 USO DE LA TECNOLOGIA CRISPR/CAS9 PARA LA IDENTIFICACION DE N... 171K€ Cerrado

Líder del proyecto

INSTITUTE OF CANCER RESEARCH THE ROYAL CANCER... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 231K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Several new therapies have been recently approved for the treatment of castration-resistant prostate cancer (CRPC) but drug resistance invariably develops and eventually causes death. Currently, the knowledge on the molecular mechanisms underlying resistance is limited; this is an area of urgent unmet medical need to allow improved treatments for patients. This study proposes a multidisciplinary effort led by the Marie-Curie fellow that will aim to identify genomic aberrations associated with drug resistance. We hypothesize that disseminated circulating tumor cells (CTCs) and DNA (CTD) from blood and plasma will contain real-time genetic information about the changes occurring in the tumor and can be used as an early biomarker of progression or responsiveness to treatment, with minimal invasiveness and discomfort to the patient. Firstly, next generation sequencing data of fresh-frozen CRPC biopsies collected prior to, and after progression on abiraterone and/or enzalutamide treatment and patient-matched archival hormone therapy-naïve samples collected at The Institute of Cancer Research, will be analyzed together with the computational oncology group at University of Trento (PI: Dr Demichelis). Second, single CTC isolation will be performed using a research protocol that is novel and developed in collaboration with Dr Terstappen (University of Twente) and Dr Tibbe (biotechnology company Aquamarijn) in the setting of the FP7 grant CTCtrap. The fellow aims to genetically characterize CTCs and CTD over time by high-throughput targeted deep sequencing to elucidate the processes underlying metastasis and evolution of resistance in prostate cancer. Thirdly, the fellow will perform studies on selected genomic aberrations to functionally confirm their role. The results could identify novel therapeutic targets and inform on the development of assays to select patients for a specific treatment.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores